​

Day One Biopharmaceuticals Stock (NASDAQ:DAWN)

ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$10.65

52W Range

$5.63 - $13.20

50D Avg

$10.63

200D Avg

$8.10

Market Cap

$1.09B

Avg Vol (3M)

$2.58M

Beta

-1.26

Div Yield

-

DAWN Company Profile

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

181

IPO Date

May 27, 2021

Website

DAWN Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24
Product$155.42M$57.22M
License$2.76M$73.94M

Fiscal year ends in Dec 25 | Currency in USD

DAWN Financial Summary

Dec 25Dec 24Dec 23
Revenue$158.18M$131.16M-
Operating Income$-127.75M$-217.27M$-206.06M
Net Income$-107.32M$-95.50M$-188.92M
EBITDA$-127.75M$-86.32M$-188.53M
Basic EPS$-1.04$-1.02$-2.37
Diluted EPS$-1.04$-1.02$-2.37

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 24, 26 | 4:30 PM
Q3 25Nov 04, 25 | 4:30 PM
Q2 25Aug 05, 25 | 4:30 PM

Peer Comparison

TickerCompany
VIRVir Biotechnology, Inc.
VALNValneva SE
RZLTRezolute, Inc.
ERASErasca, Inc.
TYRATyra Biosciences, Inc.
AVBPArriVent BioPharma, Inc. Common Stock
REPLReplimune Group, Inc.
ARVNArvinas, Inc.
GERNGeron Corporation